TNGX
Tango Therapeutics·NASDAQ
--
--(--)
--
--(--)
TNGX fundamentals
Tango Therapeutics (TNGX) released its earnings on Mar 5, 2026: revenue was 0 (YoY -100.00%), missed estimates; EPS was -0.29 (YoY +17.14%), beat estimates.
Revenue / YoY
0
-100.00%
EPS / YoY
-0.29
+17.14%
Report date
Mar 5, 2026
EPS
Actual | -0.28 | -0.25 | -0.29 | -0.28 | -0.33 | -0.33 | -0.32 | -0.23 | -0.23 | -0.32 | -0.35 | -0.24 | -0.27 | -0.35 | -0.36 | -0.35 | 0.14 | -0.29 |
Forecast | -0.284 | -0.264 | -0.272 | -0.316 | -0.3167 | -0.355 | -0.3517 | -0.326 | -0.337 | -0.274 | -0.31 | -0.345 | -0.3667 | -0.338 | -0.3501 | -0.3438 | -0.0506 | -0.3182 |
Surprise | +1.41% | +5.30% | -6.62% | +11.39% | -4.20% | +7.04% | +9.01% | +29.45% | +31.75% | -16.79% | -12.90% | +30.43% | +26.37% | -3.55% | -2.83% | -1.80% | +376.68% | +8.86% |
Revenue
Actual | 6.79M | 5.72M | 5.76M | 5.77M | 6.92M | 6.41M | 5.77M | 14.60M | 10.73M | 5.43M | 6.47M | 19.88M | 11.61M | 4.12M | 5.39M | 3.18M | 53.81M | 0 |
Forecast | 6.51M | 6.57M | 5.83M | 5.66M | 5.64M | 6.32M | 6.77M | 7.19M | 7.59M | 8.24M | 7.50M | 7.63M | 8.07M | 8.02M | 6.73M | 6.70M | 53.80M | 500.40K |
Surprise | +4.32% | -13.06% | -1.31% | +1.97% | +22.64% | +1.44% | -14.83% | +103.08% | +41.40% | -34.12% | -13.76% | +160.42% | +43.90% | -48.64% | -19.84% | -52.55% | +0.02% | -100.00% |
Earnings Call
You can ask Aime
What is Tango Therapeutics's gross profit margin?What factors drove the changes in Tango Therapeutics's revenue and profit?What guidance did Tango Therapeutics's management provide for the next earnings period?What does Tango Therapeutics do and what are its main business segments?What is the market's earnings forecast for Tango Therapeutics next quarter?What were the key takeaways from Tango Therapeutics's earnings call?What is the revenue and EPS growth rate for Tango Therapeutics year over year?What were the key takeaways from Tango Therapeutics’s earnings call?
